Latest News for LZAGY
H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.
Lonza Group AG (LZAGY) Q2 2026 Earnings Call Transcript
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Lonza Group Ag (LZAGY). But which of these two stocks is more attractive to value investors?
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LZAGY.
Senate Trading
No Senate trades found for LZAGY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.